Literature DB >> 24277828

Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model.

Jason M Warfel1, Lindsey I Zimmerman, Tod J Merkel.   

Abstract

Pertussis is a highly contagious respiratory illness caused by the bacterial pathogen Bordetella pertussis. Pertussis rates in the United States have been rising and reached a 50-y high of 42,000 cases in 2012. Although pertussis resurgence is not completely understood, we hypothesize that current acellular pertussis (aP) vaccines fail to prevent colonization and transmission. To test our hypothesis, infant baboons were vaccinated at 2, 4, and 6 mo of age with aP or whole-cell pertussis (wP) vaccines and challenged with B. pertussis at 7 mo. Infection was followed by quantifying colonization in nasopharyngeal washes and monitoring leukocytosis and symptoms. Baboons vaccinated with aP were protected from severe pertussis-associated symptoms but not from colonization, did not clear the infection faster than naïve animals, and readily transmitted B. pertussis to unvaccinated contacts. Vaccination with wP induced a more rapid clearance compared with naïve and aP-vaccinated animals. By comparison, previously infected animals were not colonized upon secondary infection. Although all vaccinated and previously infected animals had robust serum antibody responses, we found key differences in T-cell immunity. Previously infected animals and wP-vaccinated animals possess strong B. pertussis-specific T helper 17 (Th17) memory and Th1 memory, whereas aP vaccination induced a Th1/Th2 response instead. The observation that aP, which induces an immune response mismatched to that induced by natural infection, fails to prevent colonization or transmission provides a plausible explanation for the resurgence of pertussis and suggests that optimal control of pertussis will require the development of improved vaccines.

Entities:  

Keywords:  IL-17; T-cell memory; adaptive immunity; animal models; whooping cough

Mesh:

Substances:

Year:  2013        PMID: 24277828      PMCID: PMC3896208          DOI: 10.1073/pnas.1314688110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  51 in total

1.  Pertussis epidemiology in Australia over the decade 1995-2005--trends by region and age group.

Authors:  Helen E Quinn; Peter B McIntyre
Journal:  Commun Dis Intell Q Rep       Date:  2007-06

2.  Epidemic pertussis in 2012--the resurgence of a vaccine-preventable disease.

Authors:  James D Cherry
Journal:  N Engl J Med       Date:  2012-08-15       Impact factor: 91.245

3.  Pertussis outbreaks and pertussis vaccines: new insights, new concerns, new recommendations?

Authors:  Gregory A Poland
Journal:  Vaccine       Date:  2012-11-19       Impact factor: 3.641

4.  Waning immunity to pertussis following 5 doses of DTaP.

Authors:  Sara Y Tartof; Melissa Lewis; Cynthia Kenyon; Karen White; Andrew Osborn; Juventila Liko; Elizabeth Zell; Stacey Martin; Nancy E Messonnier; Thomas A Clark; Tami H Skoff
Journal:  Pediatrics       Date:  2013-03-11       Impact factor: 7.124

5.  Impact of rapid leukodepletion on the outcome of severe clinical pertussis in young infants.

Authors:  Helen E Rowlands; Allan P Goldman; Karen Harrington; Ann Karimova; Joe Brierley; Nigel Cross; Sophie Skellett; Mark J Peters
Journal:  Pediatrics       Date:  2010-09-06       Impact factor: 7.124

6.  Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines.

Authors:  B D Meade; A Deforest; K M Edwards; T A Romani; F Lynn; C H O'Brien; C B Swartz; G F Reed; M A Deloria
Journal:  Pediatrics       Date:  1995-09       Impact factor: 7.124

7.  Waning protection after fifth dose of acellular pertussis vaccine in children.

Authors:  Nicola P Klein; Joan Bartlett; Ali Rowhani-Rahbar; Bruce Fireman; Roger Baxter
Journal:  N Engl J Med       Date:  2012-09-13       Impact factor: 91.245

8.  Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines.

Authors:  C M Ausiello; F Urbani; A la Sala; R Lande; A Cassone
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

9.  Decreased leukocyte accumulation and delayed Bordetella pertussis clearance in IL-6-/- mice.

Authors:  Xuqing Zhang; Tania Goel; Laura L Goodfield; Sarah J Muse; Eric T Harvill
Journal:  J Immunol       Date:  2011-03-11       Impact factor: 5.422

Review 10.  Re-emergence of pertussis: what are the solutions?

Authors:  Romina Libster; Kathryn M Edwards
Journal:  Expert Rev Vaccines       Date:  2012-11       Impact factor: 5.217

View more
  229 in total

Review 1.  Bordetella pertussis transmission.

Authors:  Elizabeth A Trainor; Tracy L Nicholson; Tod J Merkel
Journal:  Pathog Dis       Date:  2015-09-14       Impact factor: 3.166

Review 2.  Waning and aging of cellular immunity to Bordetella pertussis.

Authors:  Inonge van Twillert; Wanda G H Han; Cécile A C M van Els
Journal:  Pathog Dis       Date:  2015-09-13       Impact factor: 3.166

Review 3.  Strategies and new developments to control pertussis, an actual health problem.

Authors:  María Emilia Gaillard; Daniela Bottero; Griselda Moreno; Martin Rumbo; Daniela Hozbor
Journal:  Pathog Dis       Date:  2015-08-09       Impact factor: 3.166

Review 4.  Bordetella pertussis evolution in the (functional) genomics era.

Authors:  Thomas Belcher; Andrew Preston
Journal:  Pathog Dis       Date:  2015-08-21       Impact factor: 3.166

Review 5.  What to do about pertussis vaccines? Linking what we know about pertussis vaccine effectiveness, immunology and disease transmission to create a better vaccine.

Authors:  Shelly Bolotin; Eric T Harvill; Natasha S Crowcroft
Journal:  Pathog Dis       Date:  2015-08-06       Impact factor: 3.166

Review 6.  The pertussis enigma: reconciling epidemiology, immunology and evolution.

Authors:  Matthieu Domenech de Cellès; Felicia M G Magpantay; Aaron A King; Pejman Rohani
Journal:  Proc Biol Sci       Date:  2016-01-13       Impact factor: 5.349

Review 7.  No pain no gain? Adjuvant effects of alum and monophosphoryl lipid A in pertussis and HPV vaccines.

Authors:  Thomas C Mitchell; Carolyn R Casella
Journal:  Curr Opin Immunol       Date:  2017-07-17       Impact factor: 7.486

8.  Core pertussis transmission groups in England and Wales: A tale of two eras.

Authors:  Ana I Bento; Maria A Riolo; Yoon H Choi; Aaron A King; Pejman Rohani
Journal:  Vaccine       Date:  2018-02-01       Impact factor: 3.641

9.  Using age-stratified incidence data to examine the transmission consequences of pertussis vaccination.

Authors:  J C Blackwood; D A T Cummings; S Iamsirithaworn; P Rohani
Journal:  Epidemics       Date:  2016-03-19       Impact factor: 4.396

10.  Maternal and neonatal vaccination protects newborn baboons from pertussis infection.

Authors:  Jason M Warfel; James F Papin; Roman F Wolf; Lindsey I Zimmerman; Tod J Merkel
Journal:  J Infect Dis       Date:  2014-02-12       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.